XORTX Therapeutics Inc
XRTX0.747USD
+0.022+3.00%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.83MCap. mercado
PérdidaP/E TTM
Más Datos de XORTX Therapeutics Inc Compañía
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Información de la empresa
Símbolo de cotizaciónXRTX
Nombre de la empresaXORTX Therapeutics Inc
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDr. Allen W. Davidoff, Ph.D.
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 30
Dirección3710 - 33rd Street NW
CiudadCALGARY
Bolsa de valoresTSX Venture Exchange (former Canadian Ventures Exchange)
PaísCanada
Código postalT2L 2M1
Teléfono14034557727
Sitio Webhttps://www.xortx.com/
Símbolo de cotizaciónXRTX
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDr. Allen W. Davidoff, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James (Jim) Fairbairn
Mr. James (Jim) Fairbairn
Chief Financial Officer
Chief Financial Officer
6.95K
+314.44%
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James (Jim) Fairbairn
Mr. James (Jim) Fairbairn
Chief Financial Officer
Chief Financial Officer
6.95K
+314.44%
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 15 de jul
Actualizado: mar., 15 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Davidoff, Allen Warren
3.18%
Giovinazzo (Anthony)
0.25%
Van Damme (Paul Joseph)
0.19%
Other
96.38%
Accionistas
Accionistas
Proporción
Davidoff, Allen Warren
3.18%
Giovinazzo (Anthony)
0.25%
Van Damme (Paul Joseph)
0.19%
Other
96.38%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
3.41%
Other
96.59%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
17
129.44K
3.42%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
2023Q1
18
180.91K
11.39%
-170.46K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Davidoff, Allen Warren
112.26K
2.96%
+800.00
+0.72%
Jun 23, 2025
Giovinazzo (Anthony)
9.63K
0.25%
--
--
Apr 30, 2025
Van Damme (Paul Joseph)
7.11K
0.19%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Mar 31, 2025
National Bank of Canada
174.00
0%
-1.44K
-89.21%
Mar 31, 2025
Armistice Capital LLC
--
0%
-265.00K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
--
0%
-17.43K
-100.00%
Mar 31, 2025
RBC Dominion Securities, Inc.
--
0%
-1.49K
-100.00%
Mar 31, 2025
Osaic Holdings, Inc.
--
0%
-1.15K
-100.00%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Fecha
Tipo
Relación
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
